PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
REAX vs. LLY
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between REAX and LLY is 0.10, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.1

Performance

REAX vs. LLY - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Real Brokerage Inc (REAX) and Eli Lilly and Company (LLY). The values are adjusted to include any dividend payments, if applicable.

-30.00%-20.00%-10.00%0.00%10.00%SeptemberOctoberNovemberDecember2025February
-10.75%
-8.61%
REAX
LLY

Key characteristics

Sharpe Ratio

REAX:

1.34

LLY:

0.49

Sortino Ratio

REAX:

2.17

LLY:

0.88

Omega Ratio

REAX:

1.26

LLY:

1.11

Calmar Ratio

REAX:

2.21

LLY:

0.62

Martin Ratio

REAX:

4.88

LLY:

1.44

Ulcer Index

REAX:

17.44%

LLY:

10.52%

Daily Std Dev

REAX:

63.76%

LLY:

31.07%

Max Drawdown

REAX:

-74.76%

LLY:

-68.27%

Current Drawdown

REAX:

-17.72%

LLY:

-9.38%

Fundamentals

Market Cap

REAX:

$1.09B

LLY:

$779.75B

EPS

REAX:

-$0.17

LLY:

$11.74

Total Revenue (TTM)

REAX:

$914.01M

LLY:

$45.04B

Gross Profit (TTM)

REAX:

$84.42M

LLY:

$36.76B

EBITDA (TTM)

REAX:

-$2.69M

LLY:

$15.63B

Returns By Period

In the year-to-date period, REAX achieves a 19.13% return, which is significantly higher than LLY's 12.51% return.


REAX

YTD

19.13%

1M

20.70%

6M

-10.75%

1Y

90.28%

5Y*

N/A

10Y*

N/A

LLY

YTD

12.51%

1M

19.68%

6M

-8.61%

1Y

15.49%

5Y*

45.57%

10Y*

30.75%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

REAX vs. LLY — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

REAX
The Risk-Adjusted Performance Rank of REAX is 8383
Overall Rank
The Sharpe Ratio Rank of REAX is 8484
Sharpe Ratio Rank
The Sortino Ratio Rank of REAX is 8282
Sortino Ratio Rank
The Omega Ratio Rank of REAX is 7878
Omega Ratio Rank
The Calmar Ratio Rank of REAX is 9191
Calmar Ratio Rank
The Martin Ratio Rank of REAX is 8080
Martin Ratio Rank

LLY
The Risk-Adjusted Performance Rank of LLY is 6161
Overall Rank
The Sharpe Ratio Rank of LLY is 6363
Sharpe Ratio Rank
The Sortino Ratio Rank of LLY is 5555
Sortino Ratio Rank
The Omega Ratio Rank of LLY is 5555
Omega Ratio Rank
The Calmar Ratio Rank of LLY is 7070
Calmar Ratio Rank
The Martin Ratio Rank of LLY is 6262
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

REAX vs. LLY - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Real Brokerage Inc (REAX) and Eli Lilly and Company (LLY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for REAX, currently valued at 1.34, compared to the broader market-2.000.002.001.340.49
The chart of Sortino ratio for REAX, currently valued at 2.17, compared to the broader market-4.00-2.000.002.004.006.002.170.88
The chart of Omega ratio for REAX, currently valued at 1.26, compared to the broader market0.501.001.502.001.261.11
The chart of Calmar ratio for REAX, currently valued at 2.21, compared to the broader market0.002.004.006.002.210.62
The chart of Martin ratio for REAX, currently valued at 4.88, compared to the broader market0.0010.0020.0030.004.881.44
REAX
LLY

The current REAX Sharpe Ratio is 1.34, which is higher than the LLY Sharpe Ratio of 0.49. The chart below compares the historical Sharpe Ratios of REAX and LLY, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio0.001.002.003.004.005.00SeptemberOctoberNovemberDecember2025February
1.34
0.49
REAX
LLY

Dividends

REAX vs. LLY - Dividend Comparison

REAX has not paid dividends to shareholders, while LLY's dividend yield for the trailing twelve months is around 0.62%.


TTM20242023202220212020201920182017201620152014
REAX
Real Brokerage Inc
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
LLY
Eli Lilly and Company
0.62%0.67%0.78%1.07%1.23%1.75%1.96%1.95%2.46%2.77%2.37%2.84%

Drawdowns

REAX vs. LLY - Drawdown Comparison

The maximum REAX drawdown since its inception was -74.76%, which is greater than LLY's maximum drawdown of -68.27%. Use the drawdown chart below to compare losses from any high point for REAX and LLY. For additional features, visit the drawdowns tool.


-40.00%-30.00%-20.00%-10.00%0.00%SeptemberOctoberNovemberDecember2025February
-17.72%
-9.38%
REAX
LLY

Volatility

REAX vs. LLY - Volatility Comparison

Real Brokerage Inc (REAX) has a higher volatility of 12.22% compared to Eli Lilly and Company (LLY) at 7.32%. This indicates that REAX's price experiences larger fluctuations and is considered to be riskier than LLY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


5.00%10.00%15.00%20.00%SeptemberOctoberNovemberDecember2025February
12.22%
7.32%
REAX
LLY

Financials

REAX vs. LLY - Financials Comparison

This section allows you to compare key financial metrics between Real Brokerage Inc and Eli Lilly and Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab